Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EDP 1503

Next Previous
Drug Profile

EDP 1503

Alternative Names: EDP-1503

Latest Information Update: 02 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Chicago
  • Developer Evelo Biosciences; Merck KGaA; University of Chicago
  • Class Antineoplastics; Bacteria; Bifidobacteria; Immunotherapies
  • Mechanism of Action Bacteria replacements; Immunomodulators; Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Colorectal cancer; Gastrointestinal cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Triple negative breast cancer

Most Recent Events

  • 08 Dec 2025 Evelo Biosciences in collaboration with the University of Chicago and Merck Sharp & Dohme Corp terminates a Phase-II trial in Malignant melanoma (Combination therapy, Late-stage disease) in USA (PO), due to drug supply related issues (NCT03595683)
  • 11 Aug 2022 Discontinued - Phase-I/II for Bladder cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (PO)
  • 11 Aug 2022 Discontinued - Phase-I/II for Bladder cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top